Relax law on cannabis seeds for better product, Thai advocate says
Marijuana advocate Aram Limsakul on Friday called on the government to relax laws so cannabis growers could collect a variety of stock seeds for genetic development of local strains.
Share this article
He said Thailand has many experienced cannabis growers, but the law prohibits them from developing parent-stock seeds.
“We want the government to unlock the law and make it easier to make parent-stock seeds. Growers are a major part of the industry. Without good growers and good seeds, you can’t get good products,” Aram said.
He was speaking at the Cannabis Wealth seminar on the topic “Thai cannabis in the world market”, held at the Grand Hyatt Erawan Hotel in Bangkok.
Aram, a founder of the Thai cannabis growers association, also said that it was “against principle” to prohibit cannabis growers from using their product. He added that the law should encourage cannabis growers, not deter them.
“We are founding an association of professional cannabis growers to encourage illegal growers to do it legally. This way we can spread knowledge among the enterprises,” he said.
Following recent amendment of laws, people in Thailand will be allowed to grow “as many cannabis plants” as they like in their own homes from June 9, according to Public Health Minister Anutin Charnvirakul.
The cannabis grown must be of medical grade and used for medicinal purposes only. Official registration is not required for growing weed at home, but growers are advised to inform authorities so that Thailand can meet the requirements of international treatises.
However, growing cannabis for recreational use is not allowed and smoking marijuana is still prohibited.
It is currently legal in Thailand for registered companies to sell marijuana products which contain less than 0.2 per cent tetrahydrocannabinol or THC, the main psychoactive compound in marijuana that gets people “high”.
Thailand providing free cannabis plants for home cultivation
FILE – Thailand’s Public Health Minister Anutin Charnvirakul speaks at a news conference at the Public Health Ministry in Nonthaburi, Thailand, Feb. 8, 2022, after signing a measure that drops cannabis from his ministry’s list of controlled drugs. Charnvirakul, who has spearheaded the country’s drive to decriminalize cannabis, has said on Wednesday, May 11 the government will distribute 1 million of the plants free when most legal restrictions on production and possession of the drug are lifted next month. (AP Photo/Sakchai Lalit, file)
BANGKOK — Thailand’s public health minister, who has spearheaded the country’s drive to decriminalize cannabis, says the government will distribute 1 million of the plants free when most legal restrictions on production and possession of the drug are lifted next month.
Public Health Minister Anutin Charnvirakul signed a measure in February officially dropping cannabis, best known in the form of marijuana, from a list of controlled drugs. Closely regulated use of cannabis was legalized in 2018, with several restrictions gradually eased since then.
Thai officials hope that a major new cannabis industry will blossom, not only generating hundreds of millions of dollars directly each year, but also attracting foreign tourists, who have only recently begun returning in large numbers after being largely absent during the coronavirus pandemic.
When the measure becomes effective on June 9, possessing and using all parts of cannabis plants, including flowers and seeds, will be allowed. However, extracted content will remain illegal if it contains more than 0.2% of the psychoactive ingredient that produces a “high” — tetrahydrocannabinol, or THC.
Anutin declared Sunday on his Facebook page that individuals will no longer need to acquire a permit to grow cannabis at home, as long as it is declared to be for medicinal purposes and does not have THC content above the legal maximum. Thai officials have not explained how the conditions can be enforced. Anutin said with little elaboration that 1 million cannabis plants would be handed out beginning in June, and that people would be able to grow as many as they like at their homes.
Large-scale enterprises will still need permission from the country’s Food and Drug Administration to make cannabis products, which are seen as being used mainly for medicines and food additives.
The Food and Drug Administration received about 4,700 applications by late last month for licenses to import, possess, grow and produce cannabis and hemp, the Bangkok Post newspaper reported. It quoted an FDA official as saying the products planned for production include hemp seed oil, dietary supplements, beverages, seasoning sauce, jelly candy and instant food.
Anutin’s Bhumjai Thai Party, a major partner in the coalition government, campaigned in the 2019 general election for the legalization of cannabis production, saying it would aid the country’s farmers.
Growing ganja permission: a real gate-way for Thailand’s promising industrial crop?
The current revision to Thailand’s Narcotics Act (B.E. 2563) permits Thai corporations to produce cannabis (ganja) for therapeutic purposes, as well as conduct beneficial research and development in science and agriculture. While ganja possession, distribution, and use are still illegal in Thailand, the law removes certain elements of Cannabis sativa (including hemp) from the narcotic lists as of December 2020 and Thailand’s narcotics board plans to remove them totally from the lists before the last quarter of 2022. The Thai Food and Drug Administration (Thai FDA) board maintains the exclusive licensing authority to assess applications and provide authorization due to the complexity of the registration process. In this view, we analyzed the guidelines for obtaining cannabis production license, and it was apparent that the announced law was in-line with regulations set-out by many countries in terms of security and prevention of misuse. The other criteria however fall merely onto the government gains, rather than public interests. To avoid the claimed state monopoly, several types of licensing should be issued in the future, depending on the genuine purpose of the farmers. The complete regulation process and conditions for obtaining a ganja growing license in Thailand are highlighted and discussed in this review.
Apart from kratom (Mitragyna speciosa Korth) and a tablet methamphetamine or yaba, ganja or marijuana (Cannabis sativa L.) has remained the most commonly reported type of illicit drugs used in Thailand for the last 20 years (Angkurawaranon et al. 2018). In traditional alternative medicine, these plant-based medications are known for their functional properties, and Thailand is well known for having an ideal climate for production (Chouvy 2019; Tipparat et al. 2012). More importantly, since the late 1960s, Thailand has been noted for developing the unique technique for ganja growing that produces thick inflorescences dense to the stem known as “Thai sticks” (Chouvy 2019; Kravanja 2016). Nowadays, it is commonly agreed that the cannabis either hemp or ganja is from the same species of C. sativa L., and therefore, growing these plants had been prohibited in Thailand since 1979. Since 2007, however, attempts have been made to legalize hemp for textile purposes (Tipparat et al. 2014; Sommano et al. 2020). In 2018, Thai legislation formally legalized ganja as a class-5 narcotic drug and psychotropic substance for therapeutic purposes, although recreational use of the substance is still prohibited (Cannacata 2020; Kanato et al. 2020). The current permission intends to make ganja one of Thailand’s future industrial crops, with benefits for research, agriculture, tourism, and the local market, as well as protecting Thai verities’ intellectual property (Cannacata 2020). As from December 2020, certain parts of ganja and hemp (subsp. sativa) as well as their extracts and by-products from extracting process with the content of tetrahydrocannabinol (THC) no greater than 0.2% were removed from the narcotic list (Gazette and Health Mo 2020). The permission allows stem, root, leaves with no bud or florescence, hemp seed and hemp seed oil, under granted permission, to be used freely (Fig. 1). The plant parts and substances other than these are still considered drugs of psychotropic potential under the provisions of the Thai Narcotics Act (B.E. 2522) (1979). For distribution of cannabis-related drugs, the penalty is a maximum of 15 years in jail and a fine of up to 1.5 million THB, with lesser penalties for manufacturing, importation, or exportation depending on the quantity (Leechaianan and Longmire 2013; Aroonsrimorakot et al. 2019). Meanwhile, charges for cannabis-related drug usage carry a maximum sentence of 1 year in prison and a maximum fine of 20,000 THB. Nonetheless, after the legal revisions took effect in 2018, research revealed a massive increase in the number of ganja users in Thailand (Kanato et al. 2020). This number may rise in the future as the public at large becomes more aware of scientific evidence and the therapeutic effects of cannabis in the treatment of illnesses (Ratwichit and Jitkuakul 2019; Thaikla et al. 2018). The new rule allows licensed traditional medicine professionals and modern medical practitioners to dispense licensed medicinal grade cannabis products and Thai Traditional Medicine formulations (Zinboonyahgoon et al. 2020).
Ganja on class-5 narcotic drugs and psychotropic substances of the Thai government gazette effective December, 2020. Superscript digit one indicates the following: under approved permission by Thai FDA. Superscript digit two indicates the following: the Thai government listed ganja, kratom, opium, and hallucinogenic mushrooms in class-5 of narcotics classification in the Narcotics Act (Saingam et al. 2013). The removal of ganja off the lists is being examined for amendment of the Act in 2022, but it must be published in the official Royal Gazette before then (Reuters 2022). Superscript digit three indicates the following: only produced in Thailand
Although Thailand was the first country in Asia to amend its narcotics-control laws in an attempt to promote the use of cannabis for medical purposes (Zinboonyahgoon et al. 2021; Jialin et al. 2020), experts have opined that the amendment is very limited, allowing only licensed research and development with public institutes and consumption with a medical certificate, raising the question of whether it will or will not benefit the nations and, more importantly, Thai farmers (Beatty 2020; Parpart 2020). The purposes of current review are to access the status of legalization and to discuss the advancement and limitation(s) of existing regulation(s) for Thai cannabis growers. The presented information herein will be advantageous for farmers and entrepreneurs, alike, abiding by these new law and regulation.
Significant of ganja permit regulations for Thai public health
While the public is concerned about the change of Thailand’s cannabis law, legalization is exclusively for medicinal purposes or as drug regulation in general (Rägo and Santoso 2008). In 2018, the World Health Organization (WHO) expert committee on drug dependence had agreed on the appropriate level of international controls for cannabidiol (CBD), a phytocannabinoid devoid of psychoactive effects to be used for medical purposes (Mayor 2019); the Thai government has adopted this to the law a year later on February 18, 2019 (Zinboonyahgoon et al. 2020; Rehm et al. 2019). CBD has recently been studied in preclinical and clinical trials and proven to have a potential pharmacotherapy for treating symptoms of a variety of neuropsychiatric illnesses, including addiction, anxiety, psychosis, motility problems, and epilepsy (Premoli et al. 2019). This active ingredient binds to key brain receptors involved in the metabolic and neuroinflammatory pathologies and a variety of brain functions including the type-1 cannabinoid receptor (CB1R) and the type-2 cannabinoid receptor (CB2R) (Kumar et al. 2019). The metabolic syndromes are thought to be linked to a change in systemic inflammation, with CBD playing a major role in the mitigation (Mastinu et al. 2018). Patients who want to use cannabis for medical purposes must first get a prescription from a practitioner, dentist, or a registered Thai-traditional medical professional. The diagnosis must be made based on evidence-based medicinal procedures derived from highly credible research studies, clinical specialists, and the expected outcome of patients (Akasin 2019). The existing regulation’s effects for public health are primarily focused on three types of medical complications (Akasin 2019; Nonthasawadsri 2020; Suphanchaimat and Pavasuthipaisit 2018) as the following:
The conditions with highly supportive research evidences including difficult-to treat epilepsy, side effects from chemotherapy (nausea and vomiting), spasticity in multiple sclerosis, and intractable neuropathic pain and HIV
The conditions that require further scientific evidences including Parkinson’s disease, Alzheimer’s disease, demyelinating disease, anxiety disorder, and patients in a palliative care and final stage of cancer
The conditions that may be privilege from ganja treatment but without adequate research evidences
In 1985, the United States Food and Drug Administration (US FDA) approved two synthetic equivalents of THC, Marinol® (dronabinol) and Cesamet® (nabilone), for alleviating nausea and vomiting associated with cancer chemotherapy in patients who have failed to respond to conventional antiemetic therapies (Brunetti et al. 2020). In the decades later, these therapeutic cannabinoid products were used to treat different forms of chronic pains (Croxford 2003) and neurological disorders such as multiple sclerosis (Pertwee 2002), epilepsy (Cortesi and Fusar-Poli 2006), and other movement disorders (Müller-Vahl et al. 1999), following by the approval of other synthetic drugs including Syndros® (dronabinol, oral solution) and Canemes® (nabilone, capsules). In Europe, however, the herbal preparations in the forms of decoctions, oils, and sprays or simply inhaled with a vaporizer (i.e., Volcano® and pen vaporizers) are preferable (Brunetti et al. 2020; Hall 2018). After the release of the current law, Thai FDA has also approved natural cannabis products including cannabis extracts produced mainly by Government Pharmaceutical Organization (GPO), Thai traditional recipes and cannabis oil (DTAM®) manufactured by department of Thai traditional and Alternative Medicine (Nonthasawadsri 2020).
The position of Thailand regulation within the broader cannabis regulation environment across the world
Cannabis and other substances, including the herbal forms of resin, extracts, and tinctures, were included in Schedule I of the Single Convention on Narcotic Drugs, making their use, possession, production, manufacture, export, import, distribution, and commerce illegal except for medical and research purposes (Hall 2018; UN 1972). Since the early 1990s, there has been an increase in global interest in the legalization of cannabis for therapeutic purposes (Hakkarainen et al. 2015). This movement began in 1996 in California, where 215 initiatives were approved in the favor of medicinal cannabis legalization. Following that, uses of medical marijuana was allowed in 28 states in the USA, with 18 more allowing some forms of recreational marijuana usage (Dyer 2017; Hollenbeck and Uetake 2020). In the Netherlands, possession of small amounts of cannabis imposes no offense and it is among the leading countries with the altered policy to reduce the penalties relating to narcotic drugs (MacCoun and Reuter 1997). However, there are no other European Union countries which officially legalize cannabis supply for recreational purposes, but legislative models are currently purposed along with decriminalization for home cultivation in Belgium, Czech Republic, and Spain (Hughes et al. 2017; Belackova et al. 2019; Bone et al. 2018). Decriminalization for personal cultivated marijuana was also a part of the drug law (de jury) in three Australian states and territories (South Australia, Australian Capital Territory (ACT), and Northern Territory), as well as Jamaica (Belackova et al. 2019). Marijuana producers in Canada must apply for licenses through the health ministry and must pass security checks and quality-control inspections, as per the “Medical Marijuana Access Regulations” (MMAR) of 2001 (Eggertson 2013; Fischer et al. 2015). It was estimated that more than 2% of Canadian citizens relied on medical marijuana treatments and nearly hundreds of individuals had applied to become licensed growers impacting a ten billion dollars business revenue (Hollenbeck and Uetake 2020; Fischer et al. 2015). In 2018, Canadian government has passed the legalization of recreational marijuana for adults under certain regulatory in place (Cox 2018). It is generally accepted that legalizing cannabis for patients has often implemented an ever strict regime, for example, the authorities and medical professionals still request evidence-based recognition of cannabis as an approved treatment (Hakkarainen et al. 2015).
Overall, the ultimate goals of ganja legalization in Thailand are primarily to provide access to this substance to patients who rely on it for therapy, as well as to support research and development. The legalization also allows different classes of federal licensees including cultivation (both of hemp and ganja), processing, and others such as research and analytical services. The government pays less attention to the risks connected with illicit markets, juvenile access restrictions, the construction of an appropriate safety and regulatory environment, and the criminal justice system, that are all necessary. Furthermore, rather than promoting fraudulent political policy, information and ground understanding about the ganja’s use of conduct should be provided to the public. We therefore conclude that unless the legalization of ganja in Thailand is for recreational use, the current regulation is comparable with a 1961 single convention on narcotic drugs.
Permission and growing ganja in Thailand
For growers, industrial hemp and licensed cultivation of ganja, for the purposes of research and scientific investigation, is legal in many places. Furthermore, growing these plants for personal use is also allowed in some countries (Ratwichit and Jitkuakul 2019; Hakkarainen et al. 2015; Potter et al. 2015; Lenton et al. 2015). As of June 2020, Thailand’s cultivation permission was only valid for C. sativa L. used for research and domestic medical purposes, and parameters like cultivation area, growing quantity, security, detailed information, and the applicant’s criminal record had to be provided along with a duly filled application form (ONCB 2020; Puttasrijaru 2019). Only a few types of applicants are allowed, according to the protocol, including (i) the government and (ii) public universities whose mission is to conduct research, education in agriculture, medical services, or narcotics control, and (iii) Thai farmers associated with a registered community enterprise, private university, and professional individual with a valid agreement with the mentioned register public sectors (MOPH 2020). To prolong a permission, applicants must report that they have no prior criminal records involving narcotic drugs (class-5) and that their previous work progress demonstrates that they have had a consistent track record. Any change in cultivation quantity must be reported to the Thai FDA, which is part of the Ministry of Public Health (MOPH), in order to revise the agreement. Nonetheless, if the cultivation location changes, the government will consider updating the application. According to this new regulation, 2793 permissions have been granted with as many as 343 cultivation permits (as of December 2021). A number of the farmer community enterprises are involved in these permits, the majority of which have an agreement with the MOPH as a public sector counterpart (Narcotics Control Division Food And Drug Administration (FDA) 2020). After the law came into effect, it was anticipated that over 200,000 individuals were prescribed medical cannabis, with 90% of those being first-time users (Kanato et al. 2020). This has the potential to secure the medicinal cannabis industry’s status while also providing growers with a window of opportunity. However, the addiction stigma that reflects the negative perception of ganja use in Thai culture, adverse side effect, and complex system of safeguard are the challenges for cannabis industry and the success of implementation of this new law (Zinboonyahgoon et al. 2020; Ritmontree et al. 2019). The government’s license monopoly model is also seen as a barrier to private investment (Kirdphol and Junngam 2020).
Sharing the same scientific name as marijuana, hemp is known for its utilizable fiber. Additionally, the term “hemp seed” is recognized when the material is used as a source of seed oil. For ganja, the resinous blend of cannabinoids that localized mainly in the trichomes of floral tissues is used for recreational or as therapeutic drugs (Small 2015; Clarke and Merlin 2016). The international criteria, nonetheless, deems CBD as the major cannabinoid composition in the floral tissue of industrial hemp which is typically about 2% weight by weight (w/w) or less, and THC should be less than 0.3% w/w, although the European Union standard is not over 0.2% w/w (Hu et al. 2019). Ganja, on the other hand, is dominated by THC, which frequently reaches 20% w/w (Chandra et al. 2017). Apart from the differences in the levels of cannabinoid, hemp, and ganja are quite difficult to distinguish by their morphologies (Datwyler and Weiblen 2006). Sawler et al. (Sawler et al. 2015) also stated that genetic distinction, such as employing specific genes linked in THC production, is insufficient to distinguish hemp from ganja. Hemp plants are usually tall, unbranched, and grown for a high ratio of fibrous stem-to-floral material, with a higher number of flowers. Only the seed of ganja is listed as a narcotic in Thailand’s existing legislation (Gazette and Health Mo 2020). However, the basis of separation of the ganja and hemp seeds employed by the Thai government has not been clearly described.
Ganja, like all other angiosperms, has a life cycle that includes seed, seed germination, seedling, vegetative phases, and flowering (Mediavilla et al. 1998) (Fig. 3A). For the pharmaceutical industry, quality control (i.e., the content of medical-grade cannabinoids, biomass, and resin), seedling propagation is considerably less advantageous than vegetative or cutting propagation to avoid male plants and cross pollination of different varieties (Chandra et al. 2020). When sexually propagated, a stable-line germinating seed lot and a standardized growing process are crucial (Chandra et al. 2010). To initiate the rapid growth, sprouting seeds (germinating taproot) require moisture, air, and heat (Fig. 2B). The seed produces its first two leaves, also known as the cotyledons, after 2 weeks. These cotyledons are not true leaves but contain food for the young plant to survive during the first few days. The next set of leaves to appear are the “real leaves,” which resemble the classic cannabis leaves. For the first 3 weeks, the seedling(s) require a minimum of 18 h of light per day to stimulate their growth. Male plants that flower earlier are removed during the early flowering stage, and female plants are kept under the 12-h photoperiod until they reach maturity (Chandra et al. 2017; Chandra et al. 2020). In fact, when grown in hot, dry regions, the temperate hemp seedlings can transform into the narcotic cultivars (Small 2015; Bouquet 1950). Based on the current Thai law, the term ganja seed is ambiguous. However, the legal procedure requires that the applicant for growing license provides the details of seed origins with or without variety name and reports the amount of possession (ONCB 2020). Mother plants of the desired genotypes are cultivated vegetatively with an artificial 18-h artificial light supply for the asexual approach. The vegetative plants are used to produce cutting with rooting hormone, which are maintained in high humidity and continuous light to produce vigorous root system (Potter 2004) (Fig. 3C). The details of additional propagation material, like those required for seed, must be provided throughout the licensing process (ONCB 2020).
Obtaining ganja growing permit in Thailand (affective June, 2020) (ONCB 2020)